Arrowhead Research | ARWR - Debt


Arrowhead Research reported $312.77M in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
Agios Pharmaceuticals USD 40.21M 4.31M Dec/2025
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 312.77M 53.52M Dec/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Incyte USD 39.43M 982K Mar/2026
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
Ligand Pharmaceuticals USD 451.49M 494K Dec/2025
Merck USD 49.34B 7.97B Dec/2025
Moderna USD 1.31B 571M Dec/2025
Nektar Therapeutics USD 0 0 Jun/2022
Novartis USD 47B 11.62B Mar/2026
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
TG Therapeutics USD 253.71M 8.37M Dec/2025
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026
Xencor USD 187.75M 118.48M Dec/2025